Shares of Bavarian Nordic jumped 10% Thursday on rising sales expectations for its vaccine against the Mpox virus, which is surging in Africa. Bavarian Nordic said it has capacity to supply two million doses of Mpox vaccine overall this year, and to make 10 million doses by the end of 2025. The vaccine is available in the U.S. for at-risk populations.